# Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

> **NCT00279435** · PHASE2,PHASE3 · TERMINATED · sponsor: **Facet Biotech** · enrollment: 25 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** visilizumab

## Key facts

- **NCT ID:** NCT00279435
- **Lead sponsor:** Facet Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** company decision based on other studies
- **Last updated:** 2012-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00279435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00279435, "Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00279435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*